Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Daiichi Sankyo Inavir obtains manufacturing approval in Japan

Daiichi Sankyo has received Japanese approval to manufacture and market a laninamivir octanoate hydrate prodrug, Inavir dry powder inhaler 20mg, for the treatment of influenza.

Daiichi Sankyo has developed Inavir, a neuraminidase inhibitor, for the Japanese market.

Inavir directly delivers the drug to the infected airways of influenza patients and a single inhaled dose has proven to be as effective as a five-day course of oseltamivir for the treatment of influenza.

A dry powder inhaler is a device that delivers medication to the lungs in the form of a dry powder.These are an alternative to the aerosol based inhalers commonly called metered-dose inhaler which may require some procedure to allow a measured dose of powder to be ready for the patient to take.

Daiichi Sankyo is engaged in developing and selling antibacterial agents and influenza vaccines.